NCT04900961Completed
CISCO-21 Prevent and Treat Long COVID-19.
Prevention and Early Treatment of the Long-term Physical Effects of Coronarvirus-19 (COVID-19): a Randomised Clinical Trial of Resistance Exercise.
Source: ClinicalTrials.gov · Last updated 25 Feb 2025
Brief summary (registry, in English)
Many people have long-lasting symptoms after COVID-19, such as breathlessness, fatigue and chest pain. So far, research studies of treatments for COVID-19 have focused on the life-threatening acute illness; few studies look at treatments to improve long-term health after COVID-19. COVID-19, particularly when this requires a hospital admission, can lead to weight loss and muscle wasting, contributing to worse outcomes. Muscle strengthening (resistance-based) exercise could improve outcomes in the long-term.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 233 (actual)
- First submitted
- 10 May 2021
- Start date
- 1 Jun 2021
- Primary completion date
- 30 Aug 2024
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT04900961
What you commit to
- Study type: Interventional
- Participants enrolled: 233
- From 1 Jun 2021 to the primary completion date, 30 Aug 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Physiotherapy as part of standard care e.g. post intensive care unit (ICU), post high dependency unit (HDU),
- No expectation of being able to walk within 3 months
- Unable to provide informed consent,
- Unable to comply with the protocol.
- Known pregnancy
Who the study is looking for
- Virology PCR positive laboratory diagnosis and/or point of care test positive for COVID-and/or
- Positive Lateral Flow Test (confirmation from notes or by participant) and/or
- Positive COVID antibody test
- Persistent symptoms for at least 4 weeks from symptoms onset (Groups A \& B only)
- Presentation type - one of group A, B or C.
Criteria the registry did not label
- Patients will be classified according by clinical presentation:
- Non-hospitalised - Positive diagnosis with persisting symptoms for at least 4 weeks from symptoms onset leading to medical review (A\&E, Community COVID Hub) but not admission (Treatment group), B) Hospitalised, positive diagnosis, and with post-discharge, persistent symptoms for at least 4 weeks from symptoms onset (Treatment group), C) Hospitalised, positive diagnosis, and in convalescent phase in-hospital (Prevention group).
- Groups A \& B = target population for treatment of persisting symptoms post-COVID i.e. Long-COVID; Group C = Target population for prevention of Long COVID.
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Infirmary Coordinator of this site? Confirm its status | Glasgow | United Kingdom | Unknown status |
| Queen Elizabeth University Hospital Coordinator of this site? Confirm its status | Glasgow | United Kingdom | Unknown status |
Related publications
- Resistance Exercise Therapy After COVID-19 Infection: A Randomized Clinical Trial.JAMA Netw Open · 2025 · PMID 41213124
This page is information, not medical advice. Discuss any trial with your doctor.